Robert Busch, MD: EMPEROR-Reduced Topline Data and SGLT2 Class


A practicing endocrinologist discusses his reaction to topline results from EMPEROR-REDUCED and what he hopes to see in the presentation at ESC 2020.

Hear from Robert Busch, MD, as he offers his thoughts on the topline results of EMPEROR-REDUCED. Released on June 30, topline results of the study indicate use of empagliflozin (Jardiance) was associated with a reduction in the composite endpoint of death and worsening heart failure.

Scheduled to be presented almost one year after the results of DAPA-HF, full results of EMPEROR-REDUCED could definitively prove the benefit seen on heart failure is truly a class effect of SGLT2 inhibitors.

Related Videos
Video 2 - "COPD Traits Associated with Phenotypes"
Video 1 - "Why is COPD Important?"
A panel of 4 experts on HIV
A panel of 4 experts on HIV
HCPLive Five at APA 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.